Sunday, September 27, 2026

TherapeuticsMD Stock Went Down By Over 29% In The Last 21 Sessions

TherapeuticsMD Stock Went Down By Over 29% In The Last 21 Sessions

(VIANEWS) - Shares of TherapeuticsMD (NASDAQ: TXMD) slid by a staggering 29.29% in 21 sessions from $4.95 at 2023-03-03, to $3.50 at 10:30 EST on Monday, after two consecutive sessions in a row of gains. NASDAQ is sliding 0.37% to $11,588.02, following the last session's downward trend.

TherapeuticsMD's last close was $3.48, 84.87% below its 52-week high of $23.00.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $-0.666.

Volatility

TherapeuticsMD's last week, last month's, and last quarter's current intraday variation average was a negative 2.79%, a negative 2.70%, and a positive 3.27%.

TherapeuticsMD's highest amplitude of average volatility was 3.22% (last week), 3.32% (last month), and 3.27% (last quarter).

Sales Growth

TherapeuticsMD's sales growth is 27.4% for the current quarter and 62.9% for the next.

Moving Average

TherapeuticsMD's value is way under its 50-day moving average of $5.20 and way below its 200-day moving average of $6.80.

More news about TherapeuticsMD (TXMD).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com